ABSTRACT
OBJECTIVE: To know the prevalence of antibodies against hepatitis A virus (anti-HAV) in a population of children and teenagers pertaining to three municipalities of the Autonomous Community of Madrid (CAM). DESIGN: Cross-study. SITE. The study was conducted in three public schools centers of the municipalities located in the Southeast of the (CAM). PATIENTS AND OTHER PARTICIPANTS: Students between the ages of 6 and 17 whose parents authorized them to be tested. MEASUREMENTS AND MAIN RESULTS: The presence of anti-HAV antibodies in the serum of 729 students was investigated. Thirty eight of them presented a positive mark, which indicates a prevalence of 5.34%. In the males, the prevalence was 5.7% and in the females it was 5%. CONCLUSIONS: The prevalence of anti-HAV antibodies is low in our population, agreeing with the delay in the age that the infection is acquired according to various publications.
Subject(s)
Hepatitis A/epidemiology , Adolescent , Age Distribution , Child , Cross-Sectional Studies , Female , Hepatitis A/immunology , Hepatitis Antibodies/blood , Hepatovirus/immunology , Humans , Male , Prevalence , Seroepidemiologic Studies , Sex Distribution , Spain/epidemiology , Urban Population/statistics & numerical dataABSTRACT
OBJECTIVE: To know the sero-protection level existing of varicella-zoster virus in a population of children and adolescents from Madrid. METHODS: To carry out this work we have had a total 560 serum from children and adolescents between 1 and 15 years old. Later to detect the title of antibodies against the varicella zoster virus (IgG VZV), we used enzymo immuno-analysis (PLATEST). RESULTS: The 96.5% of them were positive. Distributing this percentage in a similar way for every age, we get 100% at 8, 9, 10, 11 and 15 years old; 97.5% at 5, 6, 7, 12 and 13 years; 95% at 14 years old; 92.5% at 4 years old and 85% at 1 years old and 84% at 2 years old. CONCLUSIONS: The prevalence gradually increases with the age, from 20% at 1 year old to 100% at 15, finding the smallest prevalence in 84% to reach rapidly 100%.
Subject(s)
Chickenpox/epidemiology , Adolescent , Age Factors , Antibodies, Viral/blood , Chickenpox/immunology , Child , Child, Preschool , Herpesvirus 3, Human/immunology , Humans , Infant , Prevalence , Seroepidemiologic Studies , Urban Population/statistics & numerical dataABSTRACT
OBJECTIVE: This study's main aim was to investigate the immunogenicity of genetic recombinant vaccine in children and adolescents in Madrid, with the intention of determining the length of protection according to the titer of antibodies. A second aim was that of finding the optimum vaccine dosage, in order to suggest possible courses of action leading to an adequate strategy of vaccination. DESIGN: Crossover study. SETTING: Three educational centres in Madrid. PATIENTS AND OTHERS PARTICIPANTS: 1,184 pupils between 5 and 17 years old. INTERVENTIONS: Each individual was given three doses of Engerix B recombinant vaccine in the deltoid area at 0, 1 and 6 months. The vaccine dosage was 10 micrograms for children under 12 and 20 micrograms for those aged 12 and over. MAIN MEASUREMENTS AND RESULTS: The pre-vaccination markers were determined. A month after completing the vaccination, the titer of antibodies was quantified using the Abbott laboratories' microenzyme-immunoanalysis technique. The overall seroprotection rate was 98.9%. The MGT of the titer of antibodies was 9,283.2 mUI/ml. The seroprotection rates were similar among children under 12. The rates were also similar among those who were 12 or over, with titers of antibodies showing significantly higher in the children aged 12 or over. CONCLUSIONS: Given the good results obtained, we consider that the children will be protected for about 10 years. We suggest that all children and/or adolescents should be vaccinated as a means of controlling Hepatitis B. The recommended dosage for children under 8 is 10 micrograms and for those aged 8 and over, 20 micrograms.
Subject(s)
Hepatitis B Antibodies/blood , Hepatitis B Vaccines/immunology , Vaccines, Synthetic/immunology , Adolescent , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , MaleABSTRACT
We carried out a vaccine program against Hepatitis B in scholar population aged 5 to 17 educated in 3 institutions of Madrid city/ region. Those children who followed the vaccination criteria (negative HBsAg and Anti HBc markers) were vaccinated. The vaccination regimen (Engerix B recombinant DNA vaccine) was 0-1-6 months and dose was 10 and 20 ug i.m. for those aged 6 to 13 and 13 to 17 respectively. The postvaccine serologic results (anti-HBs titer) was evaluated one month after tha last dose, at 7th month from the beginning. The variables of study were age and sex for each individual. Corresponding to these variables both seroconversion rate (percentage of patients with 10 Ul/l of-anti-HBs) and the geometric mean titer of antibodies (GMT anti-HBs titer) were determined. The overall seroconversion rate at 7th month was 99%. There is not significant association neither regarding the sex nor mean age between "responders" and "no responders". The titer of anti-HBs antibodies, expressed using the G.M.T., which was reached at 7th month was 9.283.2 UI/I. Finally, there is not correlation between age and anti-HBs antibody titer.
Subject(s)
Hepatitis B Antibodies/analysis , Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Adolescent , Carrier State/epidemiology , Chi-Square Distribution , Child , Child, Preschool , Female , Hepatitis B/epidemiology , Hepatitis B Core Antigens/immunology , Hepatitis B Surface Antigens/analysis , Humans , Immunization Schedule , Male , Prevalence , Spain , Time FactorsABSTRACT
FOUNDATION: A descriptive study has been carried out, to perform body mass index, between 2606 schoolchildren at Madrid, during 1986 to 1990. METHODS: Observational and transversal study. RESULTS: The data obtained were compared by age and sex for each year, and we calculated the body mass index percentiles for each group in the study. Mean body mass index rises with age and also 90 and 95 percentiles. CONCLUSION: The 1.5% and 0.8% of children at 6 years had BMI more than 26, for male and female respectively. At age 10, this percentages were 9.5% and 11.6% for male and female, and the results for age 13 were 16.1% and 17.8% respectively.
Subject(s)
Body Mass Index , Urban Population/statistics & numerical data , Adolescent , Age Factors , Anthropometry , Child , Cross-Sectional Studies , Female , Humans , Male , Sex Factors , SpainABSTRACT
It has been done an epidemiologic study about dental caries prevalence in a school population in Madrid. We have studied 3,608 schoolchildren. Total caries prevalence was 53.4%, according other authors. Caries is more frequent between ten years children. We also observed low prevalence in the third year of the study.
